TQB3126
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 14, 2026
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
(clinicaltrials.gov)
- P1/2 | N=306 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial • Breast Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1